Press Release
Details
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The stock option, for the purchase of up to 90,000 shares of the Company’s common stock, was granted as an inducement material to the new employee’s acceptance of employment with the Company and was approved by the Compensation Committee of the Company’s Board of Directors. The stock option was granted on
About
AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we are also advancing a program in Pompe disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005805/en/
Source:
Investor Contact:
Christopher F. Brinzey
Westwicke, an ICR Company
339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com